April 15, 2021 | Health Care | North America | Active
On 15-Apr-21, medical device maker Thermo Fisher entered into a definitive agreement to acquire PPD, a leading Contract Research Organisation (CRO). This is the second major CRO deal in as many months, following PRA Health Sciences (PRAH US) / ICON (ICLR US), announced in late February, and marks a decisive move by Thermo Fisher to become a leader in this growing and profitable space. Thermo Fisher’s all-cash offer represents a takeover premium of 24% to PPD’s closing price on 13-Apr-21, before the media disclosed talks. The deal has been approved by both companies’ boards and has already received approval by ... Deal risks assessed in this research report: • Divestiture cap of 10% of PPD sales gets tested • Unexpected in-depth reviews by antitrust regulators
Please contact us to request access to this report.